• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
187406 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
2 i! U7 h% ?" H$ [$ n+ [9 `* K2 r9 ^) k0 C: W* J
. A; u' ]& Q+ e
Sub-category:9 z( a- V: O  ?! z* |
Molecular Targets
: r( P1 K0 \. R; h5 Y. A: w6 N  K
9 a6 x6 Y( |% c# @( r
Category:
8 K7 t& y& b. d$ PTumor Biology 0 I% F9 M4 V; ?( F) t" l) h- R

* Y* ]. l1 x; b8 {: G
* o, @) w# {0 e1 l+ tMeeting:
8 f8 u- ]$ z. K/ g) X2 z2011 ASCO Annual Meeting
! X4 i( {4 {* \" U8 n: C; c- q; x/ V' f5 j# A1 d' ~5 W( s
' ^( r$ V  a/ y% ^9 j2 k. g
Session Type and Session Title:5 p2 B( p4 E, ^0 o- x# U
Poster Discussion Session, Tumor Biology
0 B; ~7 q# j; U% Y
: g7 |* {; z6 ~( @4 n$ ?& P" T
2 A! X/ d' w+ X% R" K7 rAbstract No:
: ?. e7 q  [( o: }6 p2 j5 I10517
/ D* Z  q+ u# t: Z9 j: T# b+ E2 d* e& s3 t4 P

2 E" w/ d; G; I& X3 F6 V1 Z! ?Citation:
) b, s" {- Z/ H+ k4 C' `J Clin Oncol 29: 2011 (suppl; abstr 10517)
3 `- ]% C- \( l* C: R. x4 E$ G5 Z, k6 ]
1 {1 f+ o9 W( y8 M
/ g; E% {- c% f! W) YAuthor(s):
& H/ Z2 ?! F5 \/ QJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
0 W; o" U/ K' V/ j  j, ?! l& `2 {5 Q3 b7 U3 p& t' }

: S; ?) w. G! D3 e1 ?' e, P. p
% `4 q5 P/ D7 g0 E' a  y5 q5 FAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
9 I' C" [% z1 }, Q, `) ]: S0 h- n! H1 _7 r
Abstract Disclosures5 }& k* l& M4 z* {; Q+ H  W( V" t  z9 ~
1 @* ?: }9 S' Q, `+ y8 n
Abstract:
$ r# u8 h6 n% M" X7 N* }9 t" s8 I% E* x
! }+ a. {+ f9 s$ Y/ D" Y
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation./ j& Z  F- [  K) c
8 `/ o) R, C6 j
% Y2 D' l2 y. W& M$ E
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 . T+ b# I: h3 }6 C5 T. c  B
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

- }& _( {. z* K- c4 D: F; o5 p化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 + z' h  |! a5 ]% ~
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。: X" ~9 L& }; Q0 W: y
ALK一个指标医院要900多 ...
* P6 S; `: B6 `3 ^
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?' |. x  s/ K$ M" e1 M2 v* y

4 B, ]. v, [: L  i! ^现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表